サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1794524

非結核性抗酸菌症の世界市場

Nontuberculous Mycobacterial Infections

出版日
ページ情報
英文 279 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.16円
非結核性抗酸菌症の世界市場
出版日: 2025年08月20日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 279 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

非結核性抗酸菌症の世界市場は2030年までに183億米ドルに達する見込み

2024年に140億米ドルと推定される非結核性抗酸菌症の世界市場は、2024～2030年の分析期間においてCAGR 4.5%で成長し、2030年には183億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるクラリスロマイシンは、CAGR 5.6%を記録し、分析期間終了時には71億米ドルに達すると予測されます。アジスロマイシン分野の成長率は、分析期間中CAGR 2.9%と推定されます。

米国市場は38億米ドルと推定、中国はCAGR 8.4%で成長予測

米国の非結核性抗酸菌症市場は2024年に38億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに38億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは8.4%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.8%と3.6%と予測されています。欧州では、ドイツがCAGR 2.7%で成長すると予測されています。

世界の非結核性抗酸菌症市場- 主要動向と促進要因まとめ

非結核性抗酸菌（NTM）が臨床的に注目される理由とは？

非結核性抗酸菌による感染症は、気管支拡張症、COPD、嚢胞性線維症などの慢性肺疾患患者における同定が増加しているため、関心が高まっています。これらの環境細菌は土壌、水系、バイオフィルムに存在し、持続的で治療困難な肺感染症を引き起こす可能性があります。高解像度の画像診断や喀痰培養が頻繁に行われるようになったことと相まって、呼吸器専門医の認識が高まり、世界的に確定診断が増加しています。

NTM感染症は、皮膚や軟部組織、リンパ節にも発症し、免疫不全患者では播種することがあります。原因不明の呼吸器症状があり、CTスキャンで結節性または気管支拡張性の変化が持続する患者を疑うよう促すガイドラインの更新により、臨床的認識は向上しました。このような警戒心の高まりが、より系統的なスクリーニングと臨床検査を推進し、実際の罹患率が上昇しても、感染率は上昇しているように見えます。

診断と治療の革新は患者の転帰をどのように改善しているか？

NTMの診断法は、従来の培養に基づく手法から進化しています。PCRやラインプローブアッセイなどの分子アッセイは、より迅速な菌種の同定と抗菌薬耐性の検出を可能にします。この精度の高さにより、臨床医は治療の初期段階で抗菌薬レジメンを調整することができ、治療の成功率が向上します。新規のバイオマーカーや高度な画像診断技術の調査は、臨床管理における重要な課題である、活動性感染とコロニー形成の鑑別に役立っています。

現在、治療法は複数の抗マイコバクテリア薬を組み合わせて、しばしば12ヵ月を超える長期投与を行っています。吸入アミカシンリポソーム懸濁液やオキサゾリジノン系抗菌薬などの新しい薬剤は、全身毒性を軽減した標的療法を提供します。気道確保装置や肺リハビリテーションなどの補助治療は、肺機能と治療のアドヒアランスをサポートします。臨床試験では、宿主の反応を高めて細菌負担を軽減する免疫調節薬の試験が行われており、有望な初期段階の結果が得られています。

どのようなケアモデルと管理戦略が出現しているか？

NTM感染症の管理は、肺専門医、感染症専門医、放射線科医、薬剤師を含む集学的ケアチームに依存するようになってきています。包括的なケアハブは、診断、治療開始、薬物相互作用や副作用のモニタリング、アドヒアランスのサポートなどを連携して行います。遠隔医療ツールやデジタルリマインダーは、長期的な治療コンプライアンスをモニターし、副作用を遠隔で追跡するためにも使用されています。

患者教育とサポートグループは、治療の枠組みにおいて重要性を増しています。デジタル・プラットフォームを通じた持続的な患者参加は、長期治療に伴う感情的・後方支援的課題の管理に役立ちます。医療システムは、治療結果、菌種分布、地域疫学に関するデータを収集するNTMに特化した登録の開発に着手しており、より多くの情報に基づいた意思決定とベンチマーキングを可能にしています。

非結核性抗酸菌症市場の成長は、いくつかの要因によってもたらされます。

特に高齢化や免疫不全の人々の間でNTM感染の有病率が増加しており、患者層や臨床意識が拡大しています。分子診断学の進歩により、より迅速かつ正確な菌種の同定と耐性プロファイリングが可能になりつつあります。新規抗マイコバクテリア薬や吸入デリバリーシステムの導入により、標準療法に代わる治療法が提供されつつあります。遠隔医療やデジタルアドヒアランスツールに支えられた集学的治療モデルの出現により、長期的な治療成功率が向上しています。最後に、患者登録の形成とNTMの疫学および治療に関する研究の進展が、治療の革新と医療従事者によるベストプラクティスの採用を促進しています。

セグメント

薬剤タイプ（クラリスロマイシン、アジスロマイシン、リファンピン、リファブチン、その他の薬剤タイプ）、流通チャネル（病院薬局、小売薬局、オンライン薬局）

調査対象企業の例

  • Abbott Laboratories
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BioMarin Pharmaceutical Inc.
  • Bristol Myers Squibb
  • Cipla Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Insmed Incorporated
  • Janssen（Johnson & Johnson）
  • MannKind Corporation
  • Merck & Co. Inc.
  • Novartis AG
  • Paratek Pharmaceuticals Inc.
  • Pfizer Inc.
  • RedHill Biopharma Ltd.
  • Sanofi S.A.
  • Spero Therapeutics Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Vertex Pharmaceuticals Inc.
  • Zydus Lifesciences Ltd.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界固有のSLMをクエリする代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP37514

Global Nontuberculous Mycobacterial Infections Market to Reach US$18.3 Billion by 2030

The global market for Nontuberculous Mycobacterial Infections estimated at US$14.0 Billion in the year 2024, is expected to reach US$18.3 Billion by 2030, growing at a CAGR of 4.5% over the analysis period 2024-2030. Clarithromycin, one of the segments analyzed in the report, is expected to record a 5.6% CAGR and reach US$7.1 Billion by the end of the analysis period. Growth in the Azithromycin segment is estimated at 2.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.8 Billion While China is Forecast to Grow at 8.4% CAGR

The Nontuberculous Mycobacterial Infections market in the U.S. is estimated at US$3.8 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.8 Billion by the year 2030 trailing a CAGR of 8.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.8% and 3.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.7% CAGR.

Global Nontuberculous Mycobacterial Infections Market - Key Trends & Drivers Summarized

Why Are Nontuberculous Mycobacteria (NTM) Gaining Clinical Attention?

Infections caused by nontuberculous mycobacteria have become a growing concern due to increasing identification in patients with chronic lung conditions, such as bronchiectasis, COPD, or cystic fibrosis. These environmental bacteria are found in soil, water systems, and biofilms and can cause persistent, difficult-to-treat pulmonary infections. Increased awareness among pulmonologists, coupled with more frequent use of high-resolution imaging and sputum cultures, has led to a rise in confirmed diagnoses globally.

NTM infections can also occur in skin and soft tissue, lymph nodes, and disseminated in immunocompromised individuals. Clinical recognition has improved through updated guidelines that encourage suspicion in patients with unexplained respiratory symptoms and persistent nodular or bronchiectatic changes on CT scans. This heightened vigilance has driven more systematic screening and laboratory testing, making infection rates appear to rise even as actual incidence increases.

How Are Diagnostic and Treatment Innovations Improving Patient Outcomes?

Diagnostic methods for NTM are evolving beyond traditional culture-based techniques. Molecular assays, such as PCR and line probe assays, enable faster species identification and antimicrobial resistance detection. This precision allows clinicians to tailor antibiotic regimens early in therapy, improving treatment success. Research into novel biomarkers and advanced imaging techniques is helping differentiate active infection from colonization, addressing a key challenge in clinical management.

Therapeutic approaches now combine multiple antimycobacterial agents administered for long durations, often exceeding 12 months. Newer drugs-such as inhaled amikacin liposome suspension and oxazolidinones-offer targeted therapy with reduced systemic toxicity. Adjunct treatments, including airway clearance devices and pulmonary rehabilitation, support lung function and treatment adherence. Clinical trials are testing immunomodulatory agents to boost host response and reduce bacterial burden, with promising early-stage results.

What Care Models and Management Strategies Are Emerging?

Management of NTM infections increasingly relies on multidisciplinary care teams that include pulmonologists, infectious disease specialists, radiologists, and pharmacists. Comprehensive care hubs offer coordinated diagnostics, treatment initiation, monitoring of drug interactions, side effects, and adherence support. Telehealth tools and digital reminders are also being used to monitor long-term treatment compliance and track adverse effects remotely.

Patient education and support groups are gaining importance in treatment frameworks. Sustained patient engagement through digital platforms helps manage the emotional and logistical challenges of prolonged therapy. Health systems are beginning to develop NTM-specific registries that collect data on treatment outcomes, species distribution, and regional epidemiology, enabling more informed decision-making and benchmarking.

Growth in the nontuberculous mycobacterial infections market is driven by several factors.

Increasing prevalence of NTM infections, especially among aging and immunocompromised populations, is expanding patient pools and clinical awareness. Advances in molecular diagnostics are enabling faster and more accurate species identification and resistance profiling. Introduction of novel antimycobacterial drugs and inhaled delivery systems is offering alternatives to standard therapies. Emergence of multidisciplinary care models supported by telehealth and digital adherence tools is improving long-term treatment success. Finally, formation of patient registries and growing research into NTM epidemiology and therapeutics are fostering treatment innovation and adoption of best practices by healthcare providers.

SCOPE OF STUDY:

The report analyzes the Nontuberculous Mycobacterial Infections market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Clarithromycin, Azithromycin, Rifampin, Rifabutin, Other Drug Types); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

  • Abbott Laboratories
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BioMarin Pharmaceutical Inc.
  • Bristol Myers Squibb
  • Cipla Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Insmed Incorporated
  • Janssen (Johnson & Johnson)
  • MannKind Corporation
  • Merck & Co. Inc.
  • Novartis AG
  • Paratek Pharmaceuticals Inc.
  • Pfizer Inc.
  • RedHill Biopharma Ltd.
  • Sanofi S.A.
  • Spero Therapeutics Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Vertex Pharmaceuticals Inc.
  • Zydus Lifesciences Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Nontuberculous Mycobacterial Infections - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Nontuberculous Mycobacterial (NTM) Infections Drives Demand for Targeted Diagnostics and Therapies
    • Increased Awareness and Improved Diagnostic Capabilities Lead to Higher Detection Rates of NTM Lung Disease
    • Expansion of At-Risk Populations, Including the Elderly and Immunocompromised, Fuels Market Demand
    • Advancements in Molecular and Culture-Based Diagnostic Tools Enhance Early Identification and Species Differentiation
    • Growing Prevalence of Underlying Pulmonary Conditions Like COPD and Bronchiectasis Spurs NTM Management Needs
    • Surge in Macrolide-Resistant Strains Throws the Spotlight on Development of New Antimicrobial Regimens
    • Rising Clinical Attention Toward Non-Responsive TB Cases Supports Greater NTM Testing and Surveillance
    • Emerging Role of Biofilm Research and Intracellular Pathogen Studies Improves Therapeutic Targeting
    • Regulatory Push for Drug Development in Rare and Refractory Infections Encourages Investment in NTM Therapies
    • Increasing Use of Combination Antibiotic Therapies Promotes Long-Term Treatment Management Strategies
    • Globalization of Airborne Infectious Risk Awareness Promotes Proactive Screening and Treatment Guidelines
    • Integration of Next-Generation Sequencing and Genomic Typing Enhances Pathogen Surveillance and Resistance Mapping
    • Rise in Hospital-Acquired and Post-Surgical Infections Linked to NTM Underscores Need for Enhanced Prevention
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Nontuberculous Mycobacterial Infections Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Nontuberculous Mycobacterial Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Nontuberculous Mycobacterial Infections by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Clarithromycin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Clarithromycin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Clarithromycin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Azithromycin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Azithromycin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Azithromycin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Rifampin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Rifampin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Rifampin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Rifabutin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Rifabutin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Rifabutin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Nontuberculous Mycobacterial Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • JAPAN
    • Nontuberculous Mycobacterial Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • CHINA
    • Nontuberculous Mycobacterial Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: China 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: China 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • EUROPE
    • Nontuberculous Mycobacterial Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Nontuberculous Mycobacterial Infections by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Nontuberculous Mycobacterial Infections by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • FRANCE
    • Nontuberculous Mycobacterial Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: France 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: France 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • GERMANY
    • Nontuberculous Mycobacterial Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Nontuberculous Mycobacterial Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Nontuberculous Mycobacterial Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Nontuberculous Mycobacterial Infections by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Nontuberculous Mycobacterial Infections by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Nontuberculous Mycobacterial Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • INDIA
    • Nontuberculous Mycobacterial Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: India 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: India 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Nontuberculous Mycobacterial Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Nontuberculous Mycobacterial Infections by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Nontuberculous Mycobacterial Infections by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Nontuberculous Mycobacterial Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Nontuberculous Mycobacterial Infections by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Nontuberculous Mycobacterial Infections by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • AFRICA
    • Nontuberculous Mycobacterial Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030

IV. COMPETITION